Trial Profile
A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Jul 2008
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms TAXUS-Perseus
- 07 Jul 2008 New trial record.